Outsourcing

Susan Haigney is lead editor of Pharmaceutical Technology and Pharmaceutical Technology Europe.

Articles

CDMOs and CMOs will continue to invest in biopharmaceutical services and facilities as the bio/pharmaceutical industry looks to biosimilars and personalized medicine.

Growth in Biologics Market Inspires Outsourcing

Karen Flynn rejoins Catalent as president of biologics operations; regional presidents named for US and Europe.  

Catalent Biologics Announces Senior Leadership Appointments

Phillips-Medisize has announced  that it is expanding its current Global Innovation and Development (GID) site in Struer, Denmark, to include a dedicated manufacturing development and clinical build unit.


Phillips-Medisize Grows Clinical Manufacturing Capabilities to Meet Demand

Catalent completes purchase of biologics fill-finish and oral solid dose facility in Anagni, Italy

Catalent Expands Fill-Finish Capacity

The acquisition expands Charles River’s scientific capabilities in cell therapy development.

Charles River Laboratories to Acquire HemaCare in $380-Million Deal

Cambrex reports that the acquisition by the investment group will facilitate ongoing growth.

Cambrex Sale to Premira Funds Affiliate Closes

Catalent and Ethicann Pharmaceuticals have announced a partnership aimed at developing a new combination pharmaceutical-grade CBD and THC product to treat MS spasticity using Catalent’s orally disintegrating tablet technology.


Catalent, Ethicann Partner on Fast-Dissolve Cannabinoid Treatment for MS Spasticity

The companies announced a commercial supply agreement following FDA’s accelerated approval.

Catalent to Supply BeiGene’s Brukinsa

New training facilities, laboratories, packaging, gene therapy manufacturing, and biologics manufacturing highlight Thermo Fisher Scientific expansions.

Thermo Fisher Scientific Expands Capabilities

Lubrizol Life Science Health adopts new name and opens commercial manufacturing facility.

Contract Manufacturing Services